May 4, 2017 02:00 AM EDT

GenSight vet Combal grabs $40M from Novartis, Roche group for second-wave gene therapy biotech

John Carroll

Editor & Founder

Up until some months ago, Jean-Philippe Combal had been the COO at Paris-based GenSight Biologics, focused on a closely-watched late-stage study of an experimental …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

GenSight vet Combal grabs $40M from Novartis, Roche group for second-wave gene therapy biotech

John Carroll

Editor & Founder

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Updated: Patient dies in Rocket gene therapy trial, which is put on clinical hold by FDA

Lilly to buy non-opioid pain biotech SiteOne for up to $1B

RFK Jr. ends annual Covid vaccine recommendations for kids, pregnant women

Investors pump $130M into protein degrader startup GlycoEra

Prothena’s amyloidosis drug flops again, spending and staff cuts are on the way

From weeks to days: how Aizon Intelligent Agents transform pharma validation

Gen­Sight vet Com­bal grabs $40M from No­var­tis, Roche group for sec­ond-wave gene ther­a­py biotech

Editor & Founder

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

GenSight vet Combal grabs $40M from Novartis, Roche group for second-wave gene therapy biotech